Our findings suggest that kallistatin levels are significantly correlated with improvements in neuropathic symptoms following ALA treatment, indicating a potential protective effect against oxidative stress and endothelial dysfunction. This evidence concerns the gene SERPINA4 and endothelial dysfunction.